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Abstract: Lactobacilli are among the most common microorganisms found in kefir; a traditional 
fermented milk beverage produced locally in many locations around the world. Kefir has been 
associated with a wide range of purported health benefits; such as antimicrobial activity; cholesterol 
metabolism; immunomodulation; anti-oxidative effects; anti-diabetic effects; anti-allergenic effects; 
and tumor suppression. This review critically examines and assesses these claimed benefits and 
mechanisms with regard to particular Lactobacillus species and/or strains that have been derived 
from kefir; as well as detailing further potential avenues for experimentation. 
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1. Introduction 
Kefir is a putative health-promoting probiotic drink produced through the fermentation of milk 
with kefir grains, which are composed of several fungal and bacterial species. Consumption of kefir 
has been associated with numerous health benefits, including lower levels of inflammation, anti-
carcinogenic effects, lower serum cholesterol levels, improved digestion and gut health, a reduction 
in hypertension, and regulation of reactive oxygen species. Lactobacillus species form a significant 
part of kefir grains and constitute an overwhelming majority of bacterial species present [1]. While 
kefir originated in the Caucasus region of Eastern Europe, it has spread worldwide, with artisanal 
strains being found in Asia, Africa, South America, and Western and Eastern Europe. In this review, 
we analyze the health benefits associated with the most commonly studied strains of Lactobacillus 
found in kefir. 
An initial search of the literature focusing on kefir and the associated Lactobacillus species was 
undertaken. Once the species level analysis was completed, the literature was further subdivided 
according to the individual strains within these species, and the results presented in Table 1. The 
most commonly found strains among the literature were then reviewed in greater depth and their 
purported health benefits summarized. The purported health benefits of less studied strains were 
also analyzed. This analysis focuses on Lactobacillus strains found in milk kefir, as opposed to other 
types of kefir. 
The phylogeny of the Lactobacillus species found in kefir is diverse. Based on the recent paper by 
Salvetti et al. relating to Lactobacillus taxonomy, Lactobacillus species in kefir occupy a variety of 
subgroups [2], with at least one strain being present in the Lactobacillus plantarum, Lactobacillus 
delbrueckii, Lactobacillus casei, Lactobacillus reuteri and Lactobacillus buchneri groups, with other strains 
being found amongst the Leuconostoc and Lactococcus genera. However, a significant majority of the 
kefir-derived Lactobacillus strains belonged to the Lb. delbrueckii and Lb. buchneri groups, mainly 
because of the presence of Lactobacillus kefiranofaciens and Lactobacillus kefiri species within these 
respective groups. These individual species account for a significant proportion of the Lactobacillus 
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species found in kefir. Lb. plantarum are also known to be present in significant proportions in kefir 
and have been extensively studied. 
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Table 1. List of Lactobacillus species and strains found in milk kefir. 
Lactobacillus spp. Strain and Reference Lactobacillus Phylogenetic Group 1 Type Strain  
Genome Size 
(Mb) 
Lb. plantarum 
-Lb. plantarum CIDCA 83114 (×7) [3–9] 
-Lb. plantarum CIDCA 8336 (×2) [3,8] 
-Lb. plantarum B23 (×1) [10] 
-Lb. plantarum Lp27 (×1) [11] 
-Lb. plantarum YW11 (×2) [12,13] 
-Lb. plantarum Lp09 (×1) [14] 
-Lb. plantarum Lp45 (×1) [14] 
-Lb. plantarum ATCC 10012 (×1) [15] 
-Lb. plantarum K25 (×1) [16]  
-Lb. plantarum MA2 (×4) [17–20] 
-Lb. plantarum CIDCA 8327 (×2) [8,21] 
-Lb. plantarum C4 (×7) [22–28] 
-Unspecified (×1) [29]  
-Lb. plantarum CIDCA 8337 (×1) [8] 
Lb. plantarum 
Lb. plantarum subsp. plantarum 
CGMCC 1.2437 
3.2 
Lb. kefiranofaciens 
-Lb. kefiranofaciens M1 (×8) [30–37]  
-Lb. kefiranofaciens ssp. Kefirgranum (×1) [38] 
-Lb. kefiranofaciens HL1 (×1) [39] 
-Unspecified (×6) [40–45] 
-Lb. kefiranofaciens CYC 10058 (×1) [46] 
-Lb. kefiranofaciens DD2 (×1) [15] 
-Lb kefiranofaciens JCM 6985 (×1) [47]  
-Lb. kefiranofaciens DN1 (×1) [48] 
-Lb. kefiranofaciens KCTC 5075 (×1) [49] 
-Lb. kefiranofaciens ZW3 (×1) [50] 
-Lb. kefiranofaciens ATCC 43761 (×1) [51] 
Lb. delbrueckii 
Lb. kefiranofaciens subsp. 
kefiranofaciens DSM 5016 
2.6 
Lb. paracasei 
-Lb. paracasei CIDCA 8339 (×1) [52] 
-Lb. paracasei CHB 2121 (×1) [53] 
-Lb. paracasei CIDCA 8339 (×1) [54] 
-Lb. paracasei MRS59 (×1) [55] 
-Lb. paracasei SP3 (×1) [56] 
Lb. casei Lb. paracasei subsp. paracasei DSM 5622 2.9 
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Lb. kefiri 
-Lb. kefiri CIDCA 8348 (×13) [3–7,57–64] 
-Lb. kefiri CIDCA 83111 (×2) [59,62] 
-Lb. kefiri CIDCA 83102 (×1) [52] 
-Unspecified (×4) [42,49,65,66] 
-Lb. kefiri LMG 9480 (×1) [38] 
-Lb. kefiri P-IF (×2) [67,68] 
-Lb. kefiri HL2 (×1) [39] 
-Lb. kefiri DH5 (×2) [69,70] 
-Lb. kefiri CIDCA 83115 (×1) [61] 
-Lb. kefir JCM 5818 (×3) [62–64] 
-Lb. kefiri D17 (×1) [10] 
-Lb. kefir IM002 (×1) [71] 
Lb. buchneri Lb. kefiri DSM 20587 2.2 
Lb. parakefiri -Lb. parakefiri KP91 (×1) [38] Lb. buchneri Lb. parakefiri DSM 10551 2.5 
Lb. acidophilus 
-Lb. acidophilus LA15 (×1) [10] 
-Lb. acidophilus B2-2 (×1) [72] 
-Unspecified (×2) [73,74] 
-Lb. acidophilus CYC 10051 (×1) [46] 
-Lb. acidophilus Z1L (×1) [75] 
Lb. delbrueckii Lb. acidophilus DSM 20079 2.0 
Lb. casei 
-Unspecified (×2) [29,73] 
-Lb. casei NWL63 (×1) [53] 
Lb. casei Lb. casei DSM 20011 2.8 
Lb. sunkii -Unspecified (×1) [66] Lb. buchneri Lb. sunkii DSM 19904 2.7 
Lb. johnsonii -Lb. johnsonii JCM 1022 (×1) [15] Lb. delbrueckii Lb. johnsonii ATCC 33200 1.8 
Lb. rhamnosus  Lb. rhamnosus ATCC 53103 (×1) [76] Lb. casei Lb. rhamnosus DSM 20021 2.9 
Lb. kefiranofaciens 
subsp. kefirgranum 
-Lb. kefirgranum KCTC 5086 (×1) [49] Lb. delbrueckii 
Lb. kefiranofaciens subsp. kefirgranum 
DSM 10550 
2.1 
Lb. brevis -Unspecified (×1) [75] Lb. casei Lb. brevis DSM 20054 2.5 
Lb. delbrueckii 
-Lb. delbruekii CYC 10047 (×1) [46]  
-Lb. delbrueckii subsp. Lactis CIDCA 133 (×1) [9]  
-Lb. delbrueckii ssp. bulgaricus B-30892 (×1) [77] 
Lb. delbrueckii 
Lb. delbrueckii subsp. delbrueckii DSM 
20074 
2.0 
Lb. helveticus -Lb. helveticus Z5L (×1) [75] Lb. delbrueckii Lb. helveticus CGMCC 1.1877 2.0 
Lb. bulgaricus -Unspecified (×1) [75] Lb. delbrueckii 
Lb. delbrueckii subsp. bulgaricus DSM 
20081 
1.8 
Lb. fermentum -Lb. fermentum ME-3 (×1) [78] Lb. reuteri Lb. fermentum DSM 20055 1.9 
Lb. reuteri -Lb. reuteri ATCC 53609 (×1) [76] Lb. reuteri Lb. reuteri DSM 20016 2.0 
1According to [2] Salvetti, E.; M. B. Harris, H.; Felis, G.; W. O’Toole, P. Comparative genomics reveals robust phylogroups in the genus lactobacillus as the basis for 
reclassification. 2018; Vol. 84, p AEM.00993-00918. 
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2. Results 
2.1. Lactobacillus plantarum 
2.1.1. Lactobacillus plantarum CIDCA 83114 
The kefir strain Lb. plantarum CIDCA 83114 was found across multiple studies, by the same 
group based in Argentina, to exert beneficial effects. It was studied in depth using both in vivo and 
in vitro models. Lb. plantarum CIDCA 83114 was observed to have a protective effect against pathogen 
invasion of cultured human cells, with pre-incubation of the strain with Caco-2 or HT-29 colon cell 
lines resulting in a significant reduction in the internalization of the pathogen Shigella flexneri [6]. Of 
particular note is the fact of its protective effects in both cell lines, a property not observed in other 
strains tested in this study. HT-29 cells were also transfected with a plasmid expressing GFP as a 
reporter of NF-κB induced inflammation, as previous studies have shown that S. flexneri induces 
several markers of acute inflammation via the NF-κB pathway [79]. Notably, pre-incubation of HT-
29 cells with the CIDCA 83114 strain approximately halved the S. flexneri-induced NF-κB activation 
of these cells. 
This group also completed an in vivo study using hamster models (Mesocricetus auratus) [5], due 
to its relevance as a model of human infection by Clostridium difficile [80,81]. Lb. plantarum CIDCA 
83114 was used as part of a microbial mixture (MM) of several bacterial and yeast species 
administered to hamsters in drinking water (using different dilutions at rates of 1:100 and 1:1000) 
prior to infection with C. difficile. It was found that treatment with the 1:1000 MM significantly 
reduced the proportion of animals with diarrhea and mortality. Interestingly, the 1:100 MM dilution 
result in no improvement in symptoms, suggesting too high a dosage of microbes may be 
detrimental, possibly exacerbating any inflammatory response to C. difficile. It was found that in mice 
treated with clindamycin alone, a significant number of animals suffered from diarrhea, with a 
number also dying. Administration of 1:1000 MM reduced the damage caused by clindamycin 
administration, suggesting kefir consumption could be used as a co-treatment along with antibiotic 
treatment, in addition to a prophylactic role. Histological analysis of cecal tissue also revealed that in 
animals treated with C. difficile and clindamycin, thickening of the mucosa, edema, inflammatory 
infiltrate with a predominance of neutrophils, and cryptic abscesses were observed. In animals 
treated with clindamycin alone, chronic inflammation with an infiltration of lymphocytes was 
observed. In animals treated with 1:1000 MM followed by clindamycin and C. difficile infection, no 
acute colitis occurred. Although mild thickening of the mucosa, along with slight infiltration of 
lymphocytes, was noted, in comparison to the previous two groups, the histological damage was 
significantly reduced. This study also included an in vitro analysis to test if the protective effects were 
in any way related to the effects of TcdA and TcdB (C. difficile toxins). The marker for toxin activity 
used was a cell detachment ratio. The assay found that fecal filtrate extracted from the animals treated 
with the 1:1000 MM had low levels of cell detachment, comparable to levels seen in control animal 
faecal filtrate, which had no exposure to C. difficile toxins. These levels were significantly lower than 
those observed following exposure to fecal filtrate extract from animals treated only with C. difficile. 
Another group tested the effect of various potential probiotic strains, including Lb. plantarum 
CIDCA 83114, on S. flexneri invasion in Hep-2 cells [7]. It should be noted that Hep-2 cells originate 
from a laryngeal carcinoma, and not the intestine. This experiment tested the relative effect of pre-
incubation or co-incubation of Hep-2 cells with various microbial strains found in kefir against S. 
flexneri, and found that, in general, pre-incubation of Hep-2 cells exerted a significantly higher 
protective effect than co-incubation. Nevertheless, a co-incubation assay conducted with Lb. 
plantarum against S. flexneri resulted in a significant reduction in pathogen invasion (5% vs. 100% in 
the control). In contrast, other strains brought about only very modest reductions compared to the 
100% control (Lb. kefiri CIDCA 8348: 99%, Lc. lactis CIDCA 8221: 97%, Sac. cerevisiae CIDCA 8112: 
89.3%, K. marxianus CIDCA 8154: 88.6%). Pre-incubation of the Hep-2 cells resulted in an improved 
performance from all potentially-probiotic strains, with the level of internalization with Lb. plantarum 
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CIDCA 83114 being improved to 3.7% vs. the 100% control. Although the effects were less successful, 
other strains also performed well when assessed using the pre-incubation assay (Lb. kefiri CIDCA 
8348: 68.4%, Lc. lactis CIDCA 8221: 42.6%, Sac. cerevisiae CIDCA 8112: 45.3%, K. marxianus CIDCA 
8154: 32.2%). The pre-incubation dose of Lb. plantarum CIDCA 83114 was also tested for its effect on 
S. flexneri and S. sonnei invasion. For S. flexneri, 109 CFU/mL CIDCA 83114 resulted in 3.7% 
internalization, as stated above. A lower dose of 108 CFU/mL resulted in the treatment being less 
effective, leading to 12.7% internalization. Thus, for modulating cell invasion by S. flexneri, the 
treatment is dose dependent at these levels of dosage [7]. However, when the assays were performed 
with the same levels tested for S. sonnei, there was very little difference in the level of internalization, 
with treatment at 108 CFU/mL resulting in an 8.7% internalization, and 109 CFU/mL resulting in an 
8.4% internalization, i.e., a very modest, non-significant improvement. Thus, prevention of S. sonnei 
cell invasion was not dose dependent at this level. However, it significantly reduced the 
internalization of S. sonnei and demonstrated the ability of Lb. plantarum CIDCA 83114 to reduce 
internalization of more than one pathogen. 
Lb. plantarum CIDCA 83114 was also assayed as part of a two-strain and five-strain mixture [7]. 
Internalization of both Shigella strains were significantly reduced compared to the individual strains 
tested, suggesting the strains worked synergistically to exert improved positive effects. Scanning 
electron microscopy of the morphological changes seen on the surface of Hep-2 cells in response to 
various treatments was also performed. Treatment with S. flexneri resulted in removal of microvilli, 
cellular retraction, and protrusion formation along the cell surfaces. However, pre-treatment of Hep-
2 cells with the five-strain mixture prevented any morphological abnormalities induced by S. flexneri 
infection. Furthermore, treatment of Hep-2 cells with the mixture alone did not lead to any 
morphological changes, indicating its safety [7]. The authors wished to analyze the mechanisms of 
the effects observed, and so isolated the cell wall fraction of Lb. plantarum CIDCA 83114 at 
concentrations equivalent to the levels present in the five-strain mixture (109 CFU/mL), and 
preincubated the Hep-2 cells with this fraction [7]. This treatment significantly reduced the 
internalization (30% vs. 100% control) of both Shigella strains by approximately the same amount. 
However, the effect was diminished relative to the level of reduction achieved with intact Lb. 
plantarum CIDCA 83114 cells (3.7% vs. 100% control in S. flexneri, 8.4% vs. 100% control in S. sonnei). 
Nonetheless, a notable proportion of the reduction can thus be attributed to the cell wall fraction, 
and, thus, it is clear the cell wall plays a crucial role in exerting such effects. It was also noted that the 
dose of the cell wall was also significant. Cell wall extracted from a concentration of 1012 CFU/mL 
cells led to roughly 15% internalization of both Shigella strains vs. 100% control, and thus, the 
treatment was dose dependent at these levels [7]. Treatment of intact Lb. plantarum CIDCA 83114 cells 
with pepsin significantly reduced the protective effect (roughly 90% internalization vs. 100% control 
in S. flexneri, roughly 75% internalization vs. 100% control in S. sonnei), adding weight to the 
suggestion that key cell wall proteins/peptides play a crucial role in exerted the effects observed.  
In a separate study, this group also examined the ability of Lb. plantarum CIDCA 83114 to protect 
Vero cells from the effects of Escherichia coli O157:H7 strain 69160 supernatant containing type-II 
Shiga toxin [3]. It should be noted that Vero cells are not of intestinal origin, originating from a kidney 
epithelial cell line. Incubation of Vero cells with E. coli 69160 supernatant resulted in a significant 
reduction in cell viability. However, coincubation of these cells with Lb. plantarum CIDCA 83114 led 
to a significant reduction in loss of cell viability [3]. This group also tested the mechanism by which 
these effects were exerted [3] by testing the effect of intact cells vs. the cell wall fraction of this strain 
in a cell viability assay. It was found that both equivalently increased the viability of cells co-
incubated with E. coli supernatant [3]. Thus, it is likely that the cell wall of CIDCA 83114 plays a 
crucial role in conferring the anti-cytolytic benefits seen in this strain. Further testing found that the 
reduction in cytotoxicity conferred by CIDCA 83114 was completely abolished by heating the CIDCA 
83114 cells to 100 °C for 10 min, suggesting the key proteins in this process are heat sensitive [3]. 
Furthermore, coincubation with the proteolytic enzymes pepsin, proteinase K, and chymotrypsin 
resulted in a reduction in the protective effect observed in previous assays. Interestingly, 
coincubation with trypsin did not result in any reduction, thus indicating that the key proteins are 
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resistant to this enzyme. Additional testing revealed that E. coli supernatant co-incubated with 
CIDCA 83114 had a reduced level of the E. coli toxin Stx, as seen by the absence of a band 
corresponding to the B subunit of that protein on a Western Blot [3]. The resulting supernatant was 
then tested against Vero cells and was found to have a reduced cytotoxic effect compared to untreated 
E. coli supernatant. This suggests that binding or proteolysis of Stx by proteins found in the cell wall 
of CIDCA 83114 is at least partly responsible for the protective benefits observed. 
Another study investigated the protective effect of Lb. plantarum CIDCA 83114 against 
pathogenic E. coli [9]. In the cell adhesion assay, it was found that pre-treatment with 108 CFU 
L/plantarum cells/well was only effective in lowering adhesion of E. coli cells if the concentration of 
the pathogen was less than 106/well. Treatment of the Hep-2 cells with CIDCA 83114 at higher 
concentration of pathogen (107 and 108) offered no significant difference vs. no treatment. Thus, 
according to the authors, the ratio of Lactobacillus present needs to be at least 1:100 in order to exert 
protective effects. In the cell detachment assay, it was found that over 60% of Hep-2 cells detached 
when incubated with E. coli. However, when the Hep-2 cells were pre-incubated with CIDCA 83114, 
the cell detachment was significantly reduced to 20%. Furthermore, UV-killed CIDCA 83114 had very 
similar protection values to its viable counterparts, indicating it is not crucial that the Lactobacillus be 
viable. The morphological structure of the Hep-2 cells was also analyzed, using immunofluorescent 
tagging and scanning electron microscopy. Disorganization of the actin network, cell rounding, and 
cell retraction was observed in Hep-2 cells treated with E. coli. However, the extent of these alterations 
was almost completely abolished in the cells pre-treated with Lactobacillus. 
2.1.2. Lactobacillus plantarum C4 
Lb. plantarum C4 has also been studied in depth. This strain exhibited significant adhesion to 
Caco-2 cells, as well as antimicrobial activity against L. monocytogenes, Y. enterocolitica, S. typhimurium, 
and E. coli in a spot assay test [23]. The authors also conducted in vivo experiments in mice. After 
administration of this strain (at 9.4 × 109 CFU/mouse), levels of C4 were detected in the feces after one 
day, but detectable levels quickly decreased following this. The immunomodulatory effects were also 
analyzed. For this, the mice were administered cyclophosphamide (CP) in order to stimulate 
myelotoxic effects [23]. Treatment with C4 did not reverse the lower levels of peripheral blood 
leukocytes or spleen cells induced by CP treatment, but the proliferation of splenocytes, which was 
nearly abolished by CP treatment, was partially restored by C4 treatment [23].  
In a further paper by this group [24], it was shown that CP treatment resulted in a proliferation 
of segmented filamentous bacteria (SFB) in the gut of the mice, a feature that does not normally occur 
in adulthood. However, mice treated with 1 × 1010 CFU of Lb. plantarum C4 had levels of SFB 
comparable to healthy controls. Even in healthy, non-immunocompromised mice, treatment with C4 
also significantly reduced levels of SFB, suggesting that this strain has a potential effect in modulating 
host response to certain bacteria or altering the composition of the microbiome themselves.  
This group conducted another study, investigating the effect of Lb. plantarum C4 treatment in 
mice later infected with L. monocytogenes [26]. Mice were administered 5 × 107 CFU of the strain via 
gastric intubation daily for four weeks. They were then challenged with L. monocytogenes infection. 
Pre-treatment with C4 led to increased survival of the infected mice compared to non-treated 
controls. However, it was not successful in clearing the pathogen from the spleen or liver, with levels 
of the pathogen in these organs being similar to non-treated controls. Pre-treatment with C4 also had 
effects on a number of pro-inflammatory cytokines following L. monocytogenes infection. In the treated 
mice, compared to untreated controls, IL-1 and IL-6 were present in significantly higher levels in 
serum on day 2, before and after which, levels flatlined. However, in untreated mice, IL-1 levels 
underwent a gradual increase, peaking at day 4 before returning to base levels. With regard to IL-6, 
levels gradually decreased following a peak on day 2. Together, this may suggest that Lb. plantarum 
C4 primes the immune system to bacterial infections. Pre-treatment had no effect on the levels of 
TNF-α as compared to untreated controls. 
This strain was further tested in a later study by these authors [27]. They confirmed the previous 
observation that the strain inhibited the growth of both L. monocytogenes and E. coli, as seen via a spot 
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assay test. Higher concentrations of the spent culture supernatant (SCS) of C4 was also effective in 
inhibiting growth of E. coli. The SCS of C4 was effective in permeabilizing the cell envelope of E. coli, 
as evidenced by high fluorescence when treated with sytox green, a high-affinity nucleic acid stain. 
Interestingly, the treatment with SCS of this strain also led to very significant levels of cell death 
amongst HL-60 cells, a human leukemia cell line. This supernatant also exhibited high cytotoxicity 
(demonstrated by lactate dehydrogenase enzyme release) against these cells, leading the authors to 
suggest potential anti-carcinogenic effects. However, the SCS of this strain also exhibited high 
hemolytic activity, which is more consistent with non-specific cytotoxicity.  
In further experimentation, pre-treatment of mice with this strain was shown to promote 
clearance of Y. enterocolitica from Peyer’s patches [22]. Pre-treatment with C4 also appeared to prime 
immune cells to release TNF-α in response to Y. enterocolitica infection, with fecal levels being higher 
in these mice compared to untreated controls. However, such a phenomenon was not replicated in 
the plasma of these animals, suggesting a local immune response. Infection with this pathogen also 
significantly reduced fecal levels of IL-10 in untreated control animals. However, levels of IL-10 were 
not different between infected and un-infected animals when these animals had been treated with 
C4. Interestingly, among un-infected animals, treatment with C4 led to a significant decrease in IL-
10 levels compared to un-treated controls. There was also a much higher level of secretion of IgA in 
animals treated with C4 in response to pathogen infection, as compared to untreated controls, 
suggesting that this strain may have a role in priming the immune system to pathogens.  
2.1.3. Lactobacillus plantarum MA2 
The strain Lb. plantarum MA2, isolated from Tibetan kefir grains, was studied in depth in a series 
of papers from the same lab. This included an in vivo study in rats [20]. These rats were fed 
lyophilized Lb. plantarum MA2 powder at a daily dose of 1011 cells/day/rat. At the end of a five-week 
trial, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) were 
all significantly lower in the treated rats, with high-density lipoprotein cholesterol (HDL-C) showing 
no difference. These rats also exhibited significantly lower liver TC and TG levels, as well as 
significantly higher fecal weight and fecal cholesterol levels. The treated mice also showed 
significantly increased levels of lactic acid bacteria, as expected from the very high dosage received. 
Interestingly, however, levels of bifidobacteria were also significantly increased. Furthermore, both 
bifidobacteria and lactobacilli increased in relative abundance in comparison to control animals after 
a relatively similar amount of time, i.e., between days 20–24. This would seem to indicate that 
introducing lactobacilli may alter the intestinal environment in a manner that favors growth of 
bifidobacteria. 
The same group later investigated the antioxidative effects and colonization ability of this strain 
in vivo [19]. Mice were treated with D-galactose in order to induce an aging model. Randomly 
selected mice were then treated with various levels of the strain, high at 1010 CFU/day, medium at 109 
CFU/day, and low at 108 CFU/day. Bloods were then taken after six weeks. It was found that treated 
mice had lower levels of malondialdehyde (MDA), a marker for oxidative stress, and this occurred 
in a dose-dependent manner. MDA levels were also significantly reduced in the liver. However, 
treatment with this strain resulted in no change in the total antioxidant capacity (T-AOC). 
Glutathione peroxidase (GSH-Px) activity was upregulated in the blood and liver of treated mice, as 
was superoxide dismutase (SOD), with this activity being dose dependent in the liver. MA2 
antioxidant effects were also demonstrated in vitro by the same authors [18]. With regard to 
colonization, the authors used a bioluminescent tag attached to the bacterial cells administered. The 
strains’ bioluminescence levels dropped off significantly once treatment was stopped, either after a 
single dose of 3 × 108 CFU or a continuous two-week daily dose. However, microbiological analysis 
of feces retrieved from the colon and ileum was performed via serial dilution and revealed that MA2 
was still present in sufficient quantities (104–105 CFU/g) to maintain colonization 21 days after oral 
administration of the strain. Furthermore, this strain showed high-level auto-aggregation, considered 
an important characteristic in potential probiotics [17].  
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2.1.4. Other Lactobacillus plantarum STRAINS 
As per the 2013 Kakisu study above [3], it was also found that coincubation of Vero cells with 
Lb. plantarum CIDCA 8336 led to a significant reduction in the loss of cell viability of Vero cells 
exposed to E. coli 69160 supernatant. 
Another group investigated in depth the characteristics of Lb. plantarum B23 [10]. This strain 
exhibited high-level adhesion to Caco-2 cells. It was susceptible to a range of antibiotics. However, it 
was found to be resistant to tetracycline. The authors later performed in vivo studies, analyzing the 
serum lipid levels of rats treated with daily doses of 109 CFU/mL of the selected strain. They reported 
significantly lower levels of TC, TG, LDL-C, and significantly higher levels of HDL-C. Rats fed this 
strain also had lower levels of liver cholesterol content, and correspondingly higher levels of fecal 
cholesterol content [10]. Additionally, this strain colonized the gut at various points, particularly in 
the ileum, colon, and feces. Interestingly, after two weeks of stopping the treatment, the strain was 
still found in the small intestine, colon, and feces, with levels only having slightly declined [10]. 
A number of different strains that also show potential health benefits have been studied by the 
Huang group. These include Lb. plantarum Lp27 [11], Lp09, and Lp45 [14]. Lp27 has high-level 
adhesion to Caco-2 cells, a desirable characteristic in potential probiotics. It is also susceptible to a 
range of antibiotics, meaning it could easily be eradicated if required, an additional safety 
reassurance. Animals administered all strains underwent blood lipid analysis, whereby blood 
samples were taken from rats treated with a daily dose of 109 CFU/mL of their respective strain over 
the course of four weeks. All strains reduced the levels of TC, TG, and LDL-C. However, HDL-C 
levels were unaffected. Of these strains, Lp27 and Lp09 had the greatest effect and these strains also 
reduced the levels of TC and TG in the liver. Furthermore, Lp09- and Lp45-treated animals had higher 
fecal cholic acid levels compared to untreated controls. Investigating the mechanism by which such 
effects may occur, the authors found that Caco-2 cells incubated with Lp27 had a micellar cholesterol 
uptake approximately 1.5-fold lower than of untreated control cells. Furthermore, they found that 
Lp27 significantly downregulated the expression of Niemann-Pick C1-like 1 (NPC1L1; a protein that 
is critical for intestinal cholesterol absorption) mRNA in Caco-2 cells as well as in ex vivo explants of 
the small intestine. 
A paper published by a different group highlighted the anti-oxidant effect of an 
exopolysaccharide (EPS) produced by Lb. plantarum YW11 [13]. The EPS isolated from this strain 
showed high scavenging activity against hydroxyl radicals and superoxide anions. In in vivo studies 
conducted in mice, high doses of this EPS relieved oxidative stress in aging mice (induced by D-
galactose) accompanied by increased levels of glutathione peroxidase, superoxide dismutase, 
catalase, and higher overall antioxidant capacity. Treatment with EPS recovered some of the 
microbial gut diversity, which was reduced by D-galactose treatment, decreasing levels of pathogenic 
Flexispira (37.5 fold), whilst increasing levels of Blautia (36.5 fold) and Butyricicoccus (9.5 fold), which 
correspondingly decreased nitrogen oxide levels and increased short-chain fatty acid levels. 
A number of studies have identified strains with antimicrobial activity. The SCS of Lb. plantarum 
ATCC 10012 was found to inhibit growth of both Streptococcus mutans and Streptococcus sobrinus, as 
well as inhibit formation of biofilm [15]. 
Lb. plantarum CIDCA 8327 was shown in one study [8] to have an inhibitory effect on the growth 
of E. coli, Sal. enterica serovar Enteritidis, Sal. enterica serovar Tiphymurium, Sal. gallinarum, and Sh. 
sonnei, the only strain of a range of lactobacilli to have an inhibitory effect on all pathogens tested. 
This inhibition was tested by using a spot test assay.  
Lb. plantarum CIDCA 8337 displayed very high adhesion to Caco-2 cells. In a spot agar assay, it 
also demonstrated significant inhibition of E. coli and S. typhimurium [8] 
2.1.5. Studies of Unspecified Lb. plantarum Strains 
Finally, an unspecified Lb. plantarum strain, as part of a mixture contain six lactic acid bacterial 
strains, was found to enhance the cytotoxicity of NK cells against human chronic myelogenous 
leukemia K562 cells and colorectal tumor HCT116 cells [29]. Additionally, secretion of IFN-γ was 
increased in these NK cells, along with increased mRNA expression.  
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2.2. Lactobacillus kefiranofaciens 
2.2.1. Lactobacillus kefiranofaciens M1 
Across multiple studies, the strain Lb. kefiranofaciens M1 has been found to exert some 
antiallergenic-related effects regarding Th1/Th2 balance. In an early study [37], Lb. kefiranofaciens M1 
cells were found to significantly stimulate IL-6 production in a murine macrophage cell line (RAW 
264.7). Interestingly, when just the supernatant from this species was tested, it was found to 
significantly stimulate IL-6, TNF-α, IL-1β, and IL-12 at higher levels than obtained by the cells alone. 
However, in a later assay undertaken in a different murine peritoneal macrophage cell line, the cell 
responses were reversed, with treatment with the bacterial cells resulting in higher concentrations of 
cytokines compared to the supernatant. This highlights the challenge of relying on cell-line based 
analysis of health-promoting properties in gut commensals and the resulting interpretations that 
persist in the literature in this field. Regardless, Lb. kefiranofaciens M1 certainly had an effect on 
production of a number of cytokines. In the same paper, the authors partially identified the 
mechanism of IL-6 stimulation by Lb. kefiranofaciens M1 cells and their supernatant by knocking out 
the TLR-2 receptor. This resulted in a significant decrease in IL-6 production from Lb. kefiranofaciens 
M1 cells. However, IL-6 production resulting from its supernatant was unaffected, suggesting that 
the mechanism of action in this instance involved a separate receptor. 
A later study from the same group further demonstrated the cytokine inducing ability of Lb. 
kefiranofaciens M1, which induced the production of IFN-γ, TNF-α, IL-6, IL-12, and IL-1β in murine 
peritoneal macrophage cells [33]. Other than TNF-α and IL-1β, there were no differences in the 
responses elicited by live and heat-inactivated cells. Live strains stimulated higher cytokine 
production of IL-1β, while heat-inactivated strains caused higher-level production of TNF-α. This 
study also demonstrated that heat-inactivated Lb. kefiranofaciens M1 significantly reduced the levels 
of serum IgE in vivo, and that this effect was dose dependent. This effect was also demonstrated over 
a time period of four weeks. In an effort to uncover the mechanism behind such effects, the authors 
investigated the levels of certain cytokines expressed in splenocytes from the mice studied. There was 
a significant reduction in the levels of IL-5, with a corresponding increase in the levels of IL-12. This 
led the authors to suggest that Lb. kefiranofaciens M1 regulates the Th1/Th2 balance, upregulating the 
Th1 pathways while downregulating the latter [33]. It was later found that the treatment with Lb. 
kefiranofaciens M1 upregulated CD4+CD25+ regulatory T-cells, which downregulated Th2 cytokines 
[33]. Levels of CD19 were reduced and, because this is a marker for B cell lineage, suggests reduced 
B cell proliferation, which likely had an influence on the decreased levels of IgE expression. The 
authors also investigated the effect of Lb. kefiranofaciens M1 at the host response level, measuring 
expression of various genes in the Peyers’ patches of the treated mice. They found an upregulation 
of genes involved in immune responses, inflammation, and cell adhesion, along with a decrease in 
expression of genes associated with the classic complement pathway and lectin-induced pathway 
[33]. 
A further study by this group investigated the effect of Lb. kefiranofaciens M1 on the allergic 
airway response in mice [34]. A number of aspects were tested, such as the duration and dosage of 
the treatment provided. One group of mice that were administered a 108 CFU/mL dose every day for 
32 days (Course A) displayed significant reductions in the levels of IL-4, IL-13, IL-6, IL-1β, CCL20, 
and TNF-α. Mice who had been administered with the same dose for the first 14 days of the 32 days 
course (Course B) and the last 3 days of the 32 day course (Course C) displayed significantly 
decreased levels of IL-6 and TNF-α. Course A also displayed a significant increase in the levels of T-
reg cell numbers. However, as demonstrated by course B, these benefits are not permanent, and, thus, 
it is apparent that efforts need to be made to continuously administer microbial treatments. 
Additionally, course C demonstrated that short-term consumption is not effective. On this basis, the 
authors continued their experiments exclusively with the Course A treated animals [34]. They 
demonstrated that the effects observed were dose dependent, with a trend towards graduated 
decreases in the levels of various cytokines (IL-4, TNF-α, IL-5, IL-6, IL-1β, IL-17). Lb. kefiranofaciens 
M1 was also able to significantly reduce levels of IgE. Histological changes were also noted. 
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Treatment with 108 and 109 CFU/mL resulted in significantly lower levels of eosinophil infiltration in 
the lung parenchyma. Such treatment also abolished the overproduction of mucus and goblet cell 
hyperplasia detected in asthma-induced mice. Furthermore, the beneficial effects were greatest in the 
mice treated with the higher dose [34]. 
This group also investigated the effects of Lb. kefiranofaciens M1 in in vitro and in in vivo models 
of experimental colitis [32]. Initially, they analyzed the effects of Lb. kefiranofaciens M1 on the 
transepithelial electrical resistance (TEER) on an epithelial monolayer of Caco-2 cells, as a measure of 
epithelial integrity. Treatment with Lb. kefiranofaciens M1 resulted in an increase in epithelial barrier 
integrity, which was dose dependent. However, only the highest dose (108 CFU/mL) showed a 
significant change in epithelial barrier integrity vs. the control of no dose. Treatment of Caco-2 cells 
with Lb. kefiranofaciens (108 CFU/mL) also upregulated the chemokine CCL-20, which mediated the 
restitution of colonic epithelial cells. However, other similarly acting chemokines (CXCL-12 and IL-
8) did not undergo a significant change. Treatment of the monolayer with Lb. kefiranofaciens cells also 
resulted in accelerated recovery of membrane integrity following dextran sulfate sodium treatment. 
This encouraged the researchers to test this model in vivo. Mice fed the Lb. kefiranofaciens at 108 
CFU/mL had lower rectal bleeding scores and increased colon length compared to controls during 
DSS induced colitis. Histology also indicated a loss of goblet cells and disturbed mucosal architecture 
in controls, which was significantly ameliorated in treated mice. The treated mice had a significantly 
lower histological score (indicating healthier histological features) compared to control mice. Ex vivo 
colon samples were also assessed for cytokine production. Levels of IL-1β and TNF-α, pro-
inflammatory cytokines, were both significantly reduced in the treated mice, while IL-10, an anti-
inflammatory cytokine, was found to be significantly higher in treated mice. This group also 
investigated the role of TLR2 in the protective effects of Lb. kefiranofaciens treatment. The amelioration 
of rectal bleeding and colon length observed in mice treated with Lb. kefiranofaciens was not observed 
in the TLR2 knockout mice. Furthermore, Lb. kefiranofaciens treatment lead to a significant 
upregulation of NFκB when TLR2 was present in TLR2-lacking HEK-293T cells. When TLR2 was 
blocked, the increase of CCL20 induced by Lb. kefiranofaciens treatment was significantly decreased. 
In a later study, the same authors went on to conduct further experimentation in in vivo models 
[30]. Continuous intragastric administration of Lb. kefiranofaciens M1 resulted in increased ileac villus 
length/crypt depth and increased levels of goblet cells as compared to germ free (GF) and single oral 
inoculation treated mice. Treated mice also had improved intestinal bleeding scores in response to 
DSS-induced colitis when compared to non-treated mice. Histologically, there was also a significant 
difference between mice treated with Lb. kefiranofaciens vs. untreated mice when tested against DSS-
induced colitis, with a lowering in the histological score from 9 (untreated mice) to 2 (treated mice). 
This paper also showed that Lb. kefiranofaciens enhanced the immune response to TLR agonists, such 
as lipopolysaccharide (LPS) and R848, with IFN-γ and IL-12 levels significantly higher in treated mice 
relative to GF controls [30]. It should be noted, however, that this is not surprising in that any 
bacterium could be expected to elicit a stronger response than GF controls. It was also noted that it 
was unlikely that Lb. kefiranofaciens M1 colonized the gut after single oral inoculation, given that fecal 
levels dropped significantly by day 5 and being undetectable past day 7 [30]. Additionally, Lb. 
kefiranofaciens was unable to adhere to Caco-2 cells in vitro. Together, along with the previous data, 
this suggests that this strain is unable to colonize the gut and needs to be taken continuously to see 
the observed effects. However, it is likely that total confirmation could only result from an intestinal 
swab, not feces analysis alone. 
The same authors researched the effect of Lb. kefiranofaciens M1 treatment on enterohemorrhagic 
Escherichia coli (EHEC) infection [31]. Treated mice were administered 2 × 108 CFU/mL of Lb. 
kefiranofaciens intragastrically for seven days, while controls were administered phosphate buffered 
saline (PBS). The mice were then challenged with EHEC infection at various timepoints. Pre-
treatment with the Lb. kefiranofaciens strain prevented a decrease in food intake, which was caused by 
EHEC infection. Additionally, intestinal bleeding was significantly reduced in the Lb-treated group 
compared to the controls. The histological scores were also improved in the Lb-treated mice, with 
reduced atrophy of the villi, as well as an amelioration of the loss of crypts and Paneth cells. Tissue 
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edema and loss of epithelial integrity were reduced following Lactobacillus pre-treatment. 
Interestingly, pre-treatment with Lb. kefiranofaciens also resulted in a near absence of congestion of 
the renal glomeruli and kidney interstitial tissue, which was severe in the untreated but EHEC-
infected mice. Heat treatment of the Lactobacillus strain reduced its effectiveness. Pre-treatment of the 
mice with the Lactobacillus strain also reduced translocation of E. coli to the liver and spleen, and E. 
coli could not be detected in the blood of pre-treated mice, whereas significant numbers were found 
in the un-treated controls. Correspondingly, serum levels of EHEC virulence factors Stx-1 and Stx-2 
were significantly reduced in in the Lb. kefiranofaciens M1 pre-treated mice. Pre-treatment also 
resulted in increased levels of EHEC specific IgA in the feces compared to untreated controls. 
However, these increases were only detected in the feces, and were not systemic, suggesting a local 
immune response. Using in vitro intestinal cell models, the researchers determined that pre-treatment 
of Caco-2 cells with the Lactobacillus strain decreased levels of cell death when subsequently 
challenged with EHEC infection. Furthermore, this protection operated in a dose-dependent manner, 
and was reduced when the Lactobacillus strain was heat-treated. Pre-treatment also improved 
intestinal cell monolayer integrity as measured by TEER. However, pre-treatment was essential. 
Similar effects were not observed when the strain was co-cultured with the EHEC cell-free 
supernatant, nor did the co-culture method reduce levels of Stx-1/Stx-2 in the EHEC cell-free 
supernatant. 
In a later study, the oral toxicity of Lb. kefiranofaciens in rats was evaluated [35]. A high dose of 
1.8 × 1010 CFU/kg was used. At this high dose, when compared to controls, no abnormalities or 
adverse effects were observed. A number of parameters were assayed, including body weight, 
common serum biochemistry and hematology markers, as well as terminal organ weights. Organs 
and tissues were also histologically examined. Together, no adverse effects were observed with this 
high dose, indicating the regular dose of around 2 × 108 CFU/mL would appear to be within a safe 
range. However, it should be noted that such experimental observations have not been tested in 
human subjects. That being said, strain-specific consumption of kefir-isolated bacteria is unheard of 
and unlikely to occur. Nonetheless, such toxicity testing may arguably be warranted, especially if 
kefir lactobacilli were developed as single-strain probiotics.  
2.2.2. Other Lactobacillus kefiranofaciens Strains 
An early study identified Lb. kefiranofaciens 10058 as displaying a number of potentially 
beneficial properties [46]. This strain inhibited growth of all the pathogenic bacteria tested (E. coli, L. 
monocytogenes, S. typhimurium, S. enteritidis, S. flexneri, Y. enterocolitica), as determined using an agar 
spot test. It also showed high-level adhesion to Caco-2 cells. This strain was also shown to produce a 
kefiran-related exopolysaccharide. Kefiran has been shown in previous studies to retard tumor 
growth [82]. 
Another strain found to have potential health benefits is Lb. kefiranofaciens DD2 [15]. SCS of this 
strain significantly inhibited the growth of two oral pathogens (S. mutans and S. sobrinus) in nutrient 
broth. It also significantly inhibited the biofilm formation by the pathogens. Furthermore, it 
influenced the expression of several genes in S. mutans, with mRNA expression levels of proteins 
encoding for carbohydrate metabolism, adhesion, and other regulatory mechanisms being 
significantly reduced by this strain, when S. mutans cells were co-cultured with the SCS of Lb. 
kefiranofaciens DD2. 
A further study by the same group on a related strain also reported beneficial properties [48]. 
Lb. kefiranofaciens DN1 was found to increase the weight of feces and its water content in mice that 
were treated with a daily 2 × 108 dose for two weeks. Together, this is suggestive of a possible role in 
treating constipation or improving intestinal mobility. Furthermore, it altered the composition of the 
microbiome of the mice treated, with Firmicutes, Bacteroidetes, Lactobacillus, and Prevotella being found 
at significantly higher levels. Furthermore, opportunistic pathogens such as Proteobacteria, 
Enterobacteriaceae, and Clostridium were less abundant. It was also shown to produce very high levels 
of a novel EPS [88]. This purified EPS exhibited the ability to significantly reduce the levels of L. 
monocytogenes and Salmonella Enteritidis, and this ability was dose dependent. 
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Lb. kefiranofaciens KCTC 5075 displayed anti-inflammatory characteristics (as part of a three 
strain mix also containing Lb. kefirgranum KCTC 5086 and Lb. kefiri KCTC 3611 EVs) whereby its 
extracellular vesicles (EV) reduced levels of IL-8 in Caco-2 cells exposed to TNF-α [49]. Treatment 
with this strain also significantly improved the body weight, rectal bleeding, and stool consistency of 
mice with 2,4,6-trinitrobenzenesulfonic acid-induced inflammatory bowel disease. Treated mice also 
had an improved histopathological score and reduced myeloperoxidase activity, showing they were 
less inflamed.  
In an earlier study, an exopolysaccharide produced by Lb. kefiranofaciens ATCC 43761 was also 
analyzed for its potential health benefits [51]. This in vivo trial was conducted in mice who had been 
administered exopolysaccharide at a dosage of 100 mg/kg body weight/day for two, five, or seven 
consecutive days. Treatment with the exopolysaccharide at any level led to significant increases in 
the levels of IgA positive cells in the small intestine. Furthermore, after five days of treatment, the 
levels of IL-6 and IL-12 positive cells were significantly increased. This increase was also seen for IL-
10 positive cells, but only after seven days. However, regarding the large intestine, these changes 
were detected in an even quicker time-frame of only two days (except for IL-12, which was not 
assayed in the large intestine). Interestingly, these changes were also observed for TNF-α, and to a 
lesser extent IFN-γ. Serum levels of IL-4, IL-10, and IFN-γ were increased after seven days, whereas 
IL-6 was significantly increased after two days. 
2.2.3. Studies of Unspecified Lb. kefiranofaciens Strains 
A number of papers have reported on other benefits relating to this species, while not specifying 
a particular strain or strains. 
For example, one group described the effects of kefiran, a product of Lb. kefiranofaciens [44]. 
Rabbits were fed a high-cholesterol diet with or without kefiran every day for eight weeks. The total 
area of atherosclerotic lesions was reduced compared to controls, with the biggest improvements 
being seen at points in the aorta furthest from the heart. The liver also exhibited significantly lower 
levels of TC.  
Kefiran was also investigated for its immunomodulatory effects in bone marrow-derived mast 
cells (BMMCs) [43]. Pre-treatment with kefiran reduce levels of degranulation by mast cells. It also 
significantly reduced TNF-α secretion. 
Another study investigated the effect of Lactobacillus-derived extracellular vesicles (EVs) in a 
mice model of inflammatory bowel disease (IBD) [49]. The EVs were derived from different 
Lactobacillus species, including Lb. kefiranofaciens, Lb. kefiri, and Lb. kefirgranum. Confirmation that 
these vesicles were taken up by Caco-2 cells was provided by immunofluorescent microscopy. The 
Lb. kefiranofaciens EVs significantly reduced the mRNA expression levels of IL-8 in TNF-α stimulated 
Caco-2 cells. In the in vivo section of this study, mice were administered these EVs daily for 10 days, 
at either 3 × 108 CFU/mL. Half the mice were also induced with a model of inflammatory bowel 
disease by 2,4,6-trinitrobenzene sulfonic acid treatment. Mice treated with EVs showed a reduction 
in loss of body weight when compared to controls. They also suffered less rectal bleeding and had 
improved stool scores. Furthermore, these mice also had significantly healthier histological scores 
[49].  
2.3. Lactobacillus kefiri 
2.3.1. Lactobacillus kefiri CIDCA 8348 
It has been shown that Lb. kefiri CIDCA 8348 had a high auto-aggregating capability, as well as 
strong coaggregation with Salmonella [57]. This strain also showed high-level adhesion to Caco-2 cells. 
Such characteristics are desirable in a potential probiotic [57]. It was also reported that the SCS of this 
strain, along with strains CIDCA 8321, CIDCA 83113, and CIDCA 8344, significantly reduced the 
levels of adhesion and invasion of Caco-2 cells by Salmonella.  
A different study researched the role of this strain as part of a microbial mixture in relation to its 
effect on infection of C. difficile in hamsters [5]. It was found that pre-treatment with this microbial 
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mixture dramatically improved the survival of those later infected with C. difficile. Furthermore, a 
wide range of histological changes induced by C. difficile infection were absent in the mice pre-treated 
with the microbial mixture. This group used the same microbial mixture to test for effects upon 
infection by S. flexneri [6]. They found that while the microbial mixture caused a significant reduction 
in the level of Shigella invasion into Caco-2 cells, the individual strain of 8348 did not. This 
observation was corroborated by another study [7]. However, only one strain of the microbial mixture 
had any significant effect individually. This could suggest that the strains act synergistically to bring 
about the greater significant effects seen with the microbial mixture.  
Further studies by this group showed that this strain caused a statistically significant effect on 
Vero cell viability when these cells were exposed to E. coli supernatant [3].  
The same group found that surface proteins from Lb. kefiri CIDCA 8348 antagonized the 
cytotoxic effects of Clostridium difficile toxins in vitro [62]. This Lactobacillus strain was found to have 
an inhibitory effect on the ability of the SCS of C. difficile to induce cell detachment of Vero cells. This 
Lactobacillus strain also had a strong inhibitory effect on the C. difficile SCS’s ability to induce actin 
cytoskeleton disorganization. The researchers then determined the mode of action, by purifying the 
C. difficile toxins TcdA and TcdB. These toxins had a strong detachment effect in a cell detachment 
assay, which was significantly reduced by co-incubation with the surface proteins from the 
Lactobacillus. It was shown using immunofluorescent microscopy that these toxins are absorbed onto 
the surface of the Lactobacillus. Interestingly, neither heat treatment nor treatment with proteases 
reduced the ability of the surface layer proteins on the Lactobacillus to abrogate the negative effects of 
these C. difficile toxins. Only treatment with S-layer specific antibodies resulted in any reduction of 
the beneficial effects, suggesting that there is a direct interaction between the toxins and the surface 
layer proteins. Whether or not such a toxin-absorptive effect could occur sufficiently in a person 
infected with C. difficile remains to be seen. 
A more recent study by the same group reported that this Lb. kefiri strain is able to adhere to 
mucus extracted from the small intestine and colon, highlighting this strain as an interesting 
candidate for probiotic selection [61]. They also found that this strain was able to inhibit growth of 
multiple different pathogens. They spotted a suspension of this Lb. kefiri strain onto an MRS agar 
plate, which was incubated for 24 h. Following this, various pathogens were seeded into soft BHI 
agar and plated over the spotted lactobacilli. Inhibition halos where then measured. Among the 
pathogens inhibited were P. aeruginosa, Salmonella enteritidis, S. flexneri, B. cereus, L. monocytogenes, 
S. aureus, and E. faecalis. However, such anti-microbial effects are common in lactic acid bacteria tested 
in this manner and may be due to production of lactate or hydrogen peroxide [61]. 
Safety testing of this strain established that it did not cause hemolysis and was susceptible to a 
wide range of antibiotics. Mice were also treated with a daily oral dose of 2 × 108 CFU/mL, and no 
adverse health effects were observed, including no changes in levels of pro-inflammatory cytokines. 
Furthermore, no translocation of microorganisms to organs such as the liver or spleen was observed 
[59].  
Based on these promising results, the researchers conducted an in vivo study, analyzing the 
effect of the strain on host immune response and gut microbiota [58]. Mice received a daily dose of 2 
× 108 CFU/mL of the strain for either 7 or 21 days. The controls received PBS. Continuous daily 
administration of the strain resulted in an increase in the levels of IgA in the feces after a period of 14 
days. Expression levels of genes for relevant host response proteins were also examined following 
the administration of the strain. In the ileum, IL-1β and IL-17A expression was downregulated, while 
IL-10, CXCL-1, and mucin 6 were upregulated. In the colon, mucin 4 was upregulated while IFN-γ, 
GM-CSF, and IL-1β were downregulated. Gene expression was also examined in Peyer’s patches (PP) 
and mesenteric lymph nodes (mLN). In PPs, IL-23, IFN-γ, and IL-6 were downregulated. In mLN, IL-
6, IL-23, IL-17A, GM-CSF, and RORγt transcription factor was downregulated, while IL-10 was 
upregulated [58]. Ex vivo experiments were conducted to analyze the response of ileum and colon 
tissue to LPS. LPS stimulated secretion of IL-6 and GM-CSF in these tissues. However, in treated 
mice, the increase in these secretions was significantly attenuated. Furthermore, treated tissue 
showed increased levels of secretion of IL-10 in response to LPS when compared to controls [58].  
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The same authors conducted research into the effect of this strain during consumption of a 
fructose-rich diet (FRD) [60]. Mice were administered a dose (108 CFU/mL) every two days for six 
weeks. Mice on an FRD receiving this strain had significantly lower body mass compared to those 
not fed the Lactobacillus. This phenomenon was also observed with regard to triglyceride and leptin 
levels in plasma. Treatment with this strain also led to significantly lower levels of leptin mRNA 
expression in epidydimal adipose tissue compared to untreated controls. This pattern was also seen 
with mRNA expression of lipoprotein lipase (LPL) and hormone sensitive lipase (HSL). With regard 
to inflammation profile, this pattern was also seen with mRNA expression levels of IFNγ, IL-1β, and 
IL-6. 
2.3.2. Other Lactobacillus kefiri Strains 
Pre-treatment of Vero cells with the S-layer proteins of Lb. kefiri CIDCA 83111 was reported to 
have a protective effect against SCS of C. difficile [62]. It was also shown to have an inhibitory effect 
on the growth of a wide range of pathogens (P. aeruginosa, Salmonella Enteritidis, S. flexneri, L. 
monocytogenes, B. cereus, and S. aureus) as assayed via a spot agar test [59]. 
Lb. kefiri CIDCA 83102 was shown to have a high-level aggregating ability, a desirable 
characteristic for a potential probiotic [52]. Co-incubating this strain with S. enterica significantly 
reduced the ability of the latter to infect Caco-2 cells. Pre-treatment of Salmonella cells with this Lb. 
kefiri strain also reduced the ability of the pathogen to infect cells, a trait not observed in many of the 
other strains tested, even amongst those that reduced infection when co-incubated with S. enterica. 
Pre-treatment with this strain also resulted in preservation of cytoskeletal architecture, which was 
seen to be disrupted when treated with S. enterica. 
PFT is a natural mixture comprised mainly of freeze-dried Lb kefiri P-IF, also including trace 
amounts of three yeast strains. The authors of this study [68] analyzed this kefir product’s ability to 
activate dendritic cells (DC). What is particularly significant about this study is that it utilized 
donated human blood samples. PFT was found to upregulate the expression of DC surface co-
stimulatory and maturation markers CD80, CD86, and HLADR, and these increases were dose 
dependent. It also induced production of cytokines IL-6, TNF-α, and IL-10 in DCs, with the latter 
being induced by a lower Lactobacillus cell number. Secretions of IFN-γ, TNF-α, and IL-10 were also 
increased from CD4+T cells. Blood DCs were also assayed, and it was found that their secretion of IL-
29 and IFN-α were significantly increased. Blood DCs stimulated with PFT were incubated with 
CD8+T cells, which caused these T cells to upregulate CD107a and Granzyme-B expression. Both these 
markers are associated with cytotoxic T cells, which help the eradication of tumor cells and viral 
infected cells. PFT was further investigated by the authors in relation to its effect on cancer cells [67]. 
PFT was found to drastically increase levels of cell death amongst AGS cells (gastric cancer cell line). 
These cells also displayed morphological apoptotic characteristics. The specificity or biological 
relevance of this phenomenon is unclear. 
Lb. kefiri DH5 was reported to have significant cholesterol reducing effects in vitro, and, thus, 
was selected for an in vivo study [70]. Mice were administered a dose of 2 × 108 CFU of this strain 
daily for six weeks. At the end of the study, mice on a high-fat diet while being administered this 
strain (HFD-DH5 mice) had a significantly lower body weight compared to mice on a high-fat diet 
alone. These mice also had lower levels of TGs and LDL-cholesterol in their plasma. Interestingly, 
even those mice on a normal chow diet had lower levels of TGs if this strain was being administered. 
Macroscopic visual analysis of the livers of HFD-DH5 mice demonstrated similarity to those of mice 
on a regular chow diet. Histological analysis of hepatocytes of HFD-DH5 mice revealed similarities 
to those mice on a regular chow diet, with low levels of lipid droplet accumulation when compared 
to HFD mice. Adipocytes in HFD-DH5 mice were also significantly smaller than those on the high-
fat diet alone. There were also significantly higher expression levels of PPAR-α, FABP4, and CPT1 in 
adipose tissues in HFD-DH5 mice, genes that are associated with lipid oxidation. This strain’s 
supernatant was also found to inhibit the growth of Cronobacter sakazakii, a pathogen with particular 
risk to infants, in nutrient broth [69]. 
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Lb. kefiri JCM 5818 showed some ability to reduce the cytotoxic effects of C. difficile toxins TcdA 
and TcdB [62]. It also was reported to have an ability to remove cadmium, a toxic heavy metal, from 
its surrounding environment. This, in turn, could reduce its cytotoxic effects on cells in the 
surrounding environmental, such as HepG2 cells [63].  
Lb. kefiri D17 displayed a number of candidate probiotic properties [10]. While it was not 
especially adhesive to Caco-2 cells, it showed strong cholesterol assimilation abilities. In an in vivo 
study, conducted in mice that had been administered 109 CFU/mL of this strain daily for four weeks, 
TGs, TC, and LDL-C were all significantly lower in treated mice, while HDL-C was significantly 
higher. Additionally, liver cholesterol levels were also significantly lower compared to controls. 
Correspondingly, fecal cholesterol levels were significantly higher. 
Finally, pre-treatment of HT-29 cells with Lb. kefiri IM002 significantly reduced the secretion of 
IL-8 caused by S. enterica infection [71].  
2.4. Other Lactobacillus Species and Strains 
2.4.1. Lactobacillus acidophilus Strains 
Lb. acidophilus CYC 10051 from kefir showed high-level adhesion to Caco-2 cells and was able to 
inhibit the growth of a wide range of bacteria in a spot agar test [46]. 
Lb. acidophilus Z1L showed high auto-aggregation ability, a desirable characteristic for a potential 
probiotic, while also showing high-level coaggregation with E. coli [75].  
Lb. acidophilus LA15 from kefir showed some ability to lower TC, TG, and LDL-C plasma levels 
in in vivo experiments but did not increase HDL-C. Mice administered this strain also had 
significantly lower liver cholesterol levels combined with correspondingly higher fecal cholesterol 
levels [10].  
In a randomized double-blind placebo-controlled clinical trial, patients suffering from type two 
diabetes were administered 600 mL/day of kefir (containing unspecified Lb. acidophilus and 
Lactobacillus casei strains) for eight weeks. Kefir significantly reduced levels of HbA1C compared to 
baseline. However, TC, TG, and HDL-C plasma levels did not change [73].  
2.4.2. Lactobacillus paracasei Strains 
Lb. paracasei MRS59 was able to strongly inhibit growth of E. coli and S. aureus in a spot agar test. 
It also displayed significant anti-oxidant activity and went on to display significant adhesion to Caco-
2 cells, displaying probiotic potential [55].  
In milk samples inoculated with the kefir isolates Lb. paracasei subsp. paracasei CHB 2121 and Lb. 
casei NWL63, respectively, viable counts of the pathogen Mycobacterium bovis BCG decreased 
significantly, with no detectable counts recorded after 60 h of milk fermentation [53]. 
Lb. paracasei CIDCA 8339 displayed strong adhesion to Caco-2 cells [52]. It had a strong 
coaggregation with S. enterica, and strongly diminished its invasion capabilities with regard Caco-2 
cells when co-incubated with this strain. Similarly, pre-treatment of Caco-2 cells with CIDCA 8339 
also diminished S. enterica’s association and invasion to these cells. Pre-treatment also prevented the 
F-actin cytoskeleton disorganisation seen in infection of Caco-2 cells by the pathogen. 
2.4.3. Lb. delbrueckii Strains 
Lb. delbruekii CYC 10047 from kefir, which exhibited strong adhesion to Caco-2 cells, strongly 
inhibited Salmonella typhimurium attachment to these cells, while also demonstrating significant 
inhibition of the growth of several pathogenic bacteria in a spot agar test [46]. 
Incubating Hep-2 cells with Lb. delbrueckii subsp. lactis (strain CIDCA 133) for one hour prior to 
E.coli infection resulted in a minor but significant effect in reducing the amount of E. coli adhering to 
Hep-2 cells [9]. It also significantly reduced the levels of cell detachment of Hep-2 cells caused by E. 
coli infection. Furthermore, it nearly abolished the F-actin disorganization and abnormal cell 
morphology caused by E. coli infection.  
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Lb. delbrueckii ssp. bulgaricus B-30892 was tested for its effect against the cytotoxicity of C. difficile 
against Caco-2 cells [77]. Phase contrast microscopy displayed significantly diminished cytotoxic 
effects when the cell free supernatant (CFS) of strain B-30892 was co-incubated with CFS of C. difficile 
as compare to C. difficile alone. Immunofluorescent staining of live and dead Caco-2 cells following 
exposure to the CFS of these strains demonstrated that exposure of C. difficile killed a vast majority of 
the cells present, while co-incubation with strain B-30892 lead to an almost complete reverse of this 
trend. The CFS of this strain also significantly decreased the adhesion of C. difficile cells to Caco-2 
cells.  
2.4.4. Others 
Lactobacillus rhamnosus ATCC 53103 and Lb. reuteri ATCC 53609 had a small effect in reducing 
the viability of C. difficile in vitro [76]. 
Furthermore, a mixture of lactic acid bacteria including a Lb. casei strain increased NK cell 
activity, including cytotoxic activity against human colorectal tumor HCT116 cells [29]. 
3. Integrative Analysis and Knowledge Gaps 
A significant proportion of the strains tested and reviewed here were assessed for their ability 
to adhere to intestinal mucus or human cells, most commonly, but not limited to, Caco-2 cells [8–
11,14,23,46,52,55,57,61]. In some cases, these assays were used as an initial screen, leading to strains 
that did not rate highly by this metric not being investigated further [11,52,61]. While this may be an 
important metric, it overlooks the possibility that bacteria may be indirectly attached to the surface 
of the intestine through interactions with other bacteria [83,84], as part of a consortium, which may 
rate highly in this metric. This is highlighted by one study, in which Lb. kefiri D17 exhibited a strong 
effect on cholesterol levels while not being particularly adhesive to Caco-2 cells [10]. It also rules out 
the investigation of bacteria, possibly consumed regularly as part of traditional/non-sterilized foods 
or harbored in other reservoirs (such as the mouth or stomach), which may have transient but regular 
physiological effects as they pass through the gastrointestinal tract [30]. Additionally, such a 
screening process could tend to select for the strains that act primarily through competitive exclusion, 
which could lead to an overrepresentation of these strains and this mode of action. Fortunately, this 
concept was not lost on all authors [8]. Furthermore, Caco-2 cells lines are particularly prone to 
spontaneous differentiation through culture techniques [85]. Given the explosion of the microbiome 
field over the past 15 years, and especially the last 5 years, it is likely that cultured Caco-2 cell lines 
in different institutions have significant morphological and functional differences, thus making it 
difficult to compare adhesion data across labs. Additionally, a number of studies have demonstrated 
that when Caco-2 cells are cultured, they often exhibit morphological and functional features of 
enterocytes associated with the small intestine [86,87], while host-microbe interactions are located 
mainly within the large intestine/colon. Thus, this very commonly used model may limit and skew 
in its representation of intestinal cell phenotype.  
3.1. Protection from Pathogens 
Across many of the strains tested, a common characteristic reported was the ability of 
Lactobacillus strains to inhibit the growth and/or toxic effects of a wide variety of pathogenic bacteria 
[3,5–9,23,26,27,31,46,52,55,59,62,76,77]. This often occurred concurrently with Lactobacillus bacteria 
pre-treatment of host cells. 
It appears that Lb. plantarum strains act at least in part by neutralizing the toxins released by 
pathogenic bacteria [3,5]. Furthermore, it appears the cell wall of these strains are essential for this 
“mopping up” function [7,9]. However, there is also evidence that other mechanisms may be at play, 
as some strains release a molecule that directly targets the pathogenic bacterial cells [27], and also 
prime the immune system to respond faster and stronger to pathogens [22,26]. 
The available evidence suggests that Lb. kefiranofaciens strains do not act by sequestering toxins 
released by pathogens [31]. More direct mechanisms of action are likely, such as the release of a 
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bactericidal EPS [88], or possibly altering gene expression in these pathogens [15]. Modulation of the 
immune system to be more responsive to pathogens is also a putative mechanism [31]. 
Lb. kefiri strains appear to act, at least in part, through the properties of their cell wall, much like 
Lb. plantarum strains. Studies involving these strains have identified the importance of S-layer 
proteins in the mechanism of action [57], and importantly, in the sequestering of toxins [62].  
Knowledge gaps could perhaps be narrowed by comparing Lb. plantarum and Lb. kefiri genomes 
and identifying common genes for S-layer proteins, which may not be present in other species such 
as Lb. kefiranofaciens, given there was no evidence for this mechanism of action (sequestration of 
toxins) in this species. However, given these proteins are very diverse, a high degree of variation may 
be expected [89]. It is possible that analysis of the sequence of various toxins may give insight into 
structure of the corresponding S-layer protein that targets them. Interestingly, Lb. plantarum and Lb. 
kefiranofaciens strains both showed some evidence of priming the immune system to pathogens, and 
so may share common genes or sequences that code for proteins that can interact with eukaryotic 
receptors. However, the specificity of such immune priming by lactobacilli is open to question, and 
the likelihood of such a response being abrogated by tolerization upon repeated exposure needs to 
be borne in mind. 
3.2. Immunomodulation 
Immunomodulation refers to the notion that certain bacteria, usually commensals or food-borne, 
can alter the activity of the innate immune system in such a way as to promote or inhibit responses 
to a subsequent challenge. Most of the work on immunomodulation has been completed with Lb. 
kefiranofaciens M1 [30,32–34,37], although there is a little information for strains of Lb. plantarum [23] 
and Lb. kefiri [68]. 
Treatment with the supernatant of Lb. kefiranofaciens strain M1 lead to significant upregulation 
of various pro-inflammatory cytokines in macrophages. It is proposed that this effect acts through a 
molecule that binds to TLR-2 and that it has a molecular weight larger than 30 kDa. It is also ruled 
out that the effector macromolecule is peptidoglycan, which was not detectable in the supernatant. 
Temperature-dependent decreases in cytokine production suggest that the protein is not heat stable 
or that the cells need to be living to elicit their effects (i.e., it is likely the cell wall is not involved) [37]. 
Later research found that a number of genes for increased immune response, inflammation, and 
cell adhesion were upregulated by this strain, and other genes involved in the classic complement 
system and the lectin-induced pathway were downregulated. Together, this fits in with the change 
in cytokine levels, and suggests alteration to the Th1/Th2 balance in the favor of Th1 cells [33,34], 
which corroborates with decreased allergic responses and lower IgE levels. Additionally, while 
increased Th1 activation is generally associated with an increased antimicrobial response, genes 
involved in the classic complement system and lectin-induced pathway were downregulated. 
However, these pathways are innate and not specific. Downregulation suggests these bacteria have 
the ability to communicate with the human immune system in such a fashion so as to promote their 
colonization/tolerance. This may be a feature of the putative mechanism by which certain bacteria 
are tolerated in early life and become part of the stable microbiome for the majority of the lifespan, 
especially considering the human adaptive immune system does not fully mature until 2–3 years 
post-birth. Considering that these are the years in which tolerance is built, bacteria that can avoid 
activating the innate immune system (the main component of the immune active during these years) 
are more likely to elicit tolerance and long-term colonization. Bacteria that are able to do this and also 
upregulate Th1 activity later in life would benefit from the immune system being active and more 
robust against other bacteria, once again consolidating their niche in the gut.  
This strain also acted through TLR-2 to ease symptoms of DSS-induced colitis. Interestingly, 
under these circumstances, Lb. kefiranofaciens M1 decreased pro-inflammatory cytokines, suggesting 
that it may depend on environmental conditions such as the type of immune response this strain may 
elicit from host cells [32]. However, it is perhaps more likely that this strain acts through a 
strengthening of the epithelial barrier through TLR-2 activation, leading to overall reduced 
inflammation. 
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It is possible the increase in pro-inflammatory cytokines associated with lactobacilli is due to 
priming the immune system to potential pathogens, keeping it in a state of heightened 
responsiveness. This is best illustrated in a study by Fuentes et al. wherein mice whose immune 
system was compromised had a proliferation of segmented filamentous bacteria in their gut. 
However, this proliferation was abolished by treatment with Lb. plantarum C4 [24]. This strain also 
increased levels of splenocytes in these mice [23]. This theory is further supported by increased TLR 
immune response to TLR agonists in mice treated with M1 [30]. 
Immunomodulation properties are also, in some cases, anti-carcinogenic. Several strains have 
been associated with such anti-carcinogenic properties [29,67,68]. Unspecified Lb. plantarum and Lb. 
casei strains were found to upregulate cytotoxicity of NK cells against various cancer cell lines [29]. 
Lb. kefiri P-IF was also found to increase levels of cell death amongst gastric cancer cells [67]. The 
increase of co-stimulatory markers detected on DCs treated with this strain may be a putative 
mechanism of action, making detection of cancer cells more likely [68]. Additionally, these DCs, when 
incubated with CD8+T cells, upregulated CD107a and granzyme-B expression, markers of cytotoxic 
T cell activity. 
3.3. Reduction of Cholesterol Levels 
Multiple studies demonstrated the ability of lactobacilli to either reduce levels of cholesterol 
circulating in the plasma, levels of cholesterol in the liver, and/or increase levels excreted, mostly in 
response to treatment with Lb. plantarum strains [10,11,14,20], but also one Lb. kefiri strain [70]. This 
reinforced the theory of the significant role the microbiota plays in cholesterol removal, although 
some of these effects are indirect, mediated by microbial modulation of bile metabolism, which 
impacts on liver metabolism [90]. Furthermore, it appears that treatment with these bacteria leads to 
significantly lowered levels of LDL cholesterol, the type more so associated with heart disease. In 
some studies, HDL cholesterol, traditionally seen as the “good” cholesterol, was unaltered, while 
LDL was significantly reduced [10,11,14,70]. Lactobacilli also significantly reduced levels of TG in 
many of these studies. This has been further correlated with a significant decrease in levels of 
atherosclerotic lesions found in the aorta of rabbits fed a high-cholesterol diet supplemented with 
lactobacilli [44]. However, the mechanisms behind these common characteristics was not 
investigated. Thus, functional genomic studies should be undertaken of strains with and without 
these characteristics. 
3.4. Antioxidative Effects 
Several studies reported that Lb. plantarum had modest antioxidative effects, appearing to 
upregulate activity of several enzymes catalyizng free radicals [18,19]. It is thought that these effects 
may be due, at least in part, to the high scavenging ability of the EPS of these bacteria [13]. 
4. Conclusions 
Kefir has been associated with health benefits for decades. Now, there is clear scientific evidence 
emerging as to which microbes are responsible for individual effects. Lactobacilli are particularly 
characterized in this regard, being associated with protection from pathogenic bacteria, modulation 
of the immune system to potentially reduced risk of allergies and cancer, reduction of radical 
oxidative species and cholesterol levels, and potentially benefiting in diabetes. However, there are 
major deficiencies in understanding of the mechanisms behind these reported effects, and how many 
of these reported benefits translate from in vitro and pre-clinical models to human consumers. A far 
greater level of knowledge into the mechanisms, which may underpin these claimed benefits, is 
required. Comparative genomic studies of phenotypically well characterized kefir strains would be 
of additional benefit in this context, and relatively easy to carry out considering the explosion of high-
throughput sequencing technology in recent years. Identification of key genes involved in health 
benefits would be a major step forward in exploiting kefir lactobacilli. While it is acknowledged that 
the study of individual strains outside of their natural microbial consortia imposes certain significant 
Nutrients 2019, 11, 1252 20 of 24 
 
limitations, it seems pertinent from the literature that the significant variation in effect, even between 
strains of the same species, warrants further study. Certainly, beneficial effects appear synergistic 
when considering multi-species models of kefir compared to single strain or lower number models. 
However, single strain models can help identify the primary source of such effects, upon which other 
species may contribute to in a secondary, albeit significant, fashion. Furthermore, there would be 
great difficulty in attempting to tease out individual effects with full kefir on an in vivo scale. 
Additionally, considering the fact that the construction of an artificial kefir grain is a significant goal 
of the dairy industry, the knowledge afforded by such studies may one day become particularly 
relevant regarding the choice of strains to be included in such grains, perhaps eventually allowing 
relatively targeted consortia for particular functional properties. Given the mooted paradigm shift 
towards personalized medicine, such studies are likely to grow in importance. 
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